Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37153789/
Background: Emerging evidence has suggested a pro-oncogenic role of calponin 1 (CNN1) in the initiation of a variety of cancers. Despite this, CNN1 remains unknown in terms of its effects...
Conclusion: Our study has shown that CNN1 expression is aberrantly elevated in various cancers and positively correlates with angiogenesis and the immune checkpoint, contributing to cancer progression and poor prognosis. These results suggest that CNN1 could serve as a promising candidate for pan-cancer immunotherapy.
SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37108312/
The metabolic enzymes involved in one-carbon metabolism are closely associated with tumor progression and could be potential targets for cancer therapy. Recent studies showed that serine hydroxymethyltransferase 2 (SHMT2), a...
Conclusions/Relevance: Our results elucidate the novel function of SHMT2 in stabilizing HIF1α under hypoxic conditions, thus providing a potential therapeutic strategy for GC treatment.
Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting: a case report
Source : https://www.e-ce.org/journal/view.php?doi=10.5946/ce.2022.117
We report a rare case of gastric cancer presenting with a gastrocolic fistula during ramucirumab and paclitaxel combination therapy that was successfully managed with colonic stenting. A 75-year-old man was...
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36883420/
This multicenter, randomized phase II/III study evaluated the addition of the vascular endothelial growth factor receptor-2 inhibitor ramucirumab to FLOT as perioperative treatment for resectable esophagogastric adenocarcinoma. Patients received either...
Conclusions/Relevance: The combination of ramucirumab and FLOT as perioperative treatment shows efficacy signals, particularly in terms of R0 resection rates, for a study population with a high proportion of prognostically poor histological subtypes, and further evaluation in this subgroup seems warranted.
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study
Source : https://jgc-online.org/DOIx.php?id=10.5230/jgc.2023.23.e15
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study Takatsugu Ogata,Yukiya Narita,Zev A. Wainberg,Eric Van Cutsem,Kensei Yamaguchi,Yongzhe Piao,Yumin Zhao,Patrick M....
Conclusions: RAM provided a significant benefit, irrespective of LM status; however, its effect was numerically stronger in patients with LM. Therefore, RAM+PAC is a clinically meaningful therapeutic option for patients with mGEA and LM.
-
Gastric Cancer Connect3yrKey Points • Source: Journal of Gastric Cancer • Conclusions: “RAM [ramucirumab] provided a significant benefit, irrespective of LM [liver metastasis] status; however, its effect was numerically stronger in patients with LM. Therefore, RAM+PAC Show More